The Bangalore-based pharmaceutical firm, Stride Pharma Science on Monday made an announcement that it has entered into a sub-agreement with Medicines Patent Pool (MPP) to launch a generic version of Pfizer’s Covid-19 oral treatment in low and middle-income markets. This drug has received emergency use authorization for Covid-10 oral antiviral treatment by the US Food and Drug Administration (USFDA).
The generic version of the drug will be branded as Kovidax and scheduled to be launched in the markets as a part of as part of Strides’ sub-licensing agreement with MPP. The drug will be manufactured at the company’s facility in Bengaluru. Strides Pharma has said that it had already secured its active pharmaceutical ingredients supplies through a preferred partnership arrangement.
The oral drug consists of Nirmatrelvir tablets, which are co-administered with Ritonavir tablets. The treatment has been very effective in reducing the risk of hospitalization and also reduces the death chances by 89 percent within three days of symptom onset..
